A5006313543- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Inhalation and Respiratory Drug Delivery
- Cystic Fibrosis Research Advances
- Adrenal Hormones and Disorders
- Estrogen and related hormone effects
- Allergic Rhinitis and Sensitization
- Pediatric health and respiratory diseases
- Neonatal Respiratory Health Research
- Diabetes Management and Research
- Pharmaceutical studies and practices
- Lung Cancer Treatments and Mutations
- Heme Oxygenase-1 and Carbon Monoxide
- Pharmacological Effects and Assays
- Respiratory Support and Mechanisms
- Smoking Behavior and Cessation
- Helicobacter pylori-related gastroenterology studies
- Voice and Speech Disorders
- Immunodeficiency and Autoimmune Disorders
- Immune Response and Inflammation
- Intestinal and Peritoneal Adhesions
- Genetic Associations and Epidemiology
- Sleep and Work-Related Fatigue
- PI3K/AKT/mTOR signaling in cancer
AstraZeneca (Sweden)
2015-2024
AstraZeneca (Switzerland)
2024
AstraZeneca (Netherlands)
2019-2023
AstraZeneca (Spain)
2016-2017
University of Gothenburg
2005-2011
Drottning Silvias barn- och ungdomssjukhus
2005-2011
Charing Cross Hospital
1989
In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a fast-acting β2-agonist may be alternative to conventional treatment strategies.We conducted 52-week, double-blind trial involving 12 years age or older asthma. Patients were randomly assigned one three regimens: twice-daily placebo terbutaline (0.5 mg) used as needed (terbutaline group), budesonide-formoterol (200 μg budesonide and 6 formoterol) (budesonide-formoterol μg) (budesonide maintenance group). The...
Patients with mild asthma often rely on inhaled short-acting β2-agonists for symptom relief and have poor adherence to maintenance therapy. Another approach might be patients receive a fast-acting reliever plus an glucocorticoid component as-needed basis address symptoms exacerbation risk.We conducted 52-week, double-blind, multicenter trial involving 12 years of age or older who had were eligible treatment regular glucocorticoids. randomly assigned twice-daily placebo budesonide-formoterol...
IntroductionPersistent cough with sputum production is an important clinical trait in chronic obstructive pulmonary disease (COPD). We defined “frequent productive cough” based on 2 questions from the St George's Respiratory Questionnaire (SGRQ) and sought to determine its occurrence associated outcomes patients physician-assigned asthma and/or COPD NOVELTY study.MethodsFrequent was as most or several days/week for past 3 months (scoring ≥3 both SGRQ questions). Relationships baseline...
The aim of the present study was to investigate whether selective antagonism cysteine-X-cysteine chemokine receptor-2 (CXCR2) receptor has any adverse effects on key innate effector functions human neutrophils for defence against microbial pathogens.In a double-blind, crossover study, 30 healthy volunteers were randomized treatment with CXCR2 antagonist AZD5069 (100 mg) or placebo, twice daily orally 6 days. peripheral blood neutrophil count assessed at baseline, during and in response...
Asthma and chronic obstructive pulmonary disease (COPD) have overlapping clinical features share pathobiological mechanisms but are often considered distinct disorders. Prospective, observational studies across asthma, COPD asthma–COPD overlap limited. NOVELTY is a global, prospective 3-year study enrolling ∼12 000 patients ≥12 years of age from primary specialist practices in 19 countries (ClinicalTrials.gov identifier: NCT02760329 ). NOVELTY's objectives to describe patient...
Abstract Background No short patient-reported outcome (PRO) instruments assess overall health status across different obstructive lung diseases. Thus, the wording of introduction to Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) was modified permit use in asthma and/or COPD. This tool is called Airways (CAAT). Methods The psychometric properties CAAT were evaluated using baseline data from NOVELTY study (NCT02760329) patients with physician-assigned asthma, + COPD or...
In many patients with mild asthma, the low frequency of symptoms and episodic nature exacerbations make adherence to regular maintenance treatment difficult. This often leads over-reliance on short-acting β2-agonist (SABA) reliever medication under-treatment underlying inflammation, poor control asthma increased risk exacerbations. The use budesonide/formoterol 'as needed' in response may represent an alternative option for asthma.The SYmbicort Given as needed Mild Asthma (SYGMA) programme...
To assess health status in respiratory diseases, the Chronic Airways Assessment Test (CAAT) was adapted from COPD (CAT) by replacing COPD-specific wording. It has demonstrated good psychometric properties asthma and/or COPD. This cross-sectional analysis evaluated how CAAT scores are associated with clinical characteristics patients Using baseline NOVELTY data ( NCT02760329 ) for physician-assigned COPD, linear regression models were implemented to association between score (range 0–40;...
Abstract Fraction of exhaled nitric oxide (FENO) is often reduced in cystic fibrosis (CF). FENO at different expiratory flows can provide an indication the site production. The aim this study was to examine whether NO parameters are related overall (FEV 1 ) or peripheral (lung clearance index, LCI, measured by multiple breath SF 6 washout) airway function and systemic inflammation CF. Secondary compare alveolar bronchial flux calculated two mathematical models, a linear nonlinear method....
ABSTRACT Objectives: To obtain a balance in the fatty acid (FA) metabolism is important for inflammatory response and of special importance cystic fibrosis (CF), which characterized by impaired FA metabolism, chronic inflammation, infection airways. Nitric oxide (NO) has antimicrobial properties low nasal (nNO) exhaled NO (FE ), commonly reported CF that may affect bacterial status. The present study investigates effect different blends on nNO FE immunological markers patients with CF....
Abstract Oral corticosteroid use is limited by side effects, some caused off‐target actions on the mineralocorticoid receptor that disrupt electrolyte balance. AZD9567 a selective, nonsteroidal glucocorticoid modulator. The efficacy, safety, and tolerability of prednisolone were assessed in phase IIa study. Anti‐inflammatory mechanism action was also evaluated vitro monocytes from healthy donors. In this randomized, double‐blind, parallel‐group, multicenter study, patients with active...
Background: Clara cell protein 16 (CC16; secretoglobin 1A1) is an anti‐inflammatory mainly expressed in the epithelial cells airways. Objective: To compare levels of CC16 nasal lavage (NAL) from children with intermittent allergic rhinitis and healthy controls to study effect a local steroid. Methods: Thirty schoolchildren birch pollen allergy 30 same schools were included study. The NAL fluid was collected before season, during season and, for patients, after 1 week treatment Symptom scores...
This 3-part, randomised, phase 1 first-in-human study (NCT03436316) investigated the safety, tolerability and pharmacokinetics (PK) of AZD8154, a dual phosphoinositide 3-kinase (PI3K) γδ inhibitor developed as novel inhaled anti-inflammatory treatment for respiratory disease.Healthy men, women nonchildbearing potential, were enrolled to receive single multiple ascending doses AZD8154 in parts 3 study, respectively, while part 2 characterised systemic PK after intravenous (IV) dose. In 1,...
Background The Respiratory Symptoms Questionnaire (RSQ) is a novel, four-item patient-reported diagnosis-agnostic tool designed to assess the frequency of respiratory symptoms and their impact on activity, without specifying particular diagnosis. Our objective was examine its validity in patients with asthma and/or chronic obstructive pulmonary disease (COPD). Methods Baseline data were randomly sampled from who completed RSQ NOVELTY study ( ClinicalTrials.gov : NCT02760329 ). total sample...
Epithelial sodium channel (ENaC) inhibitors may offer clinical benefit in cystic fibrosis (CF); however, data are limited. We report the outcomes of a Phase I (NCT02679729) and Ib (NCT02950805) study AZD5634, novel inhaled ENaC inhibitor.A I, first-in-human, single-blind, placebo-controlled, single ascending dose, sequential dose group assessed safety, tolerability, pharmacokinetics AZD5634 healthy subjects (n=53) part A following doses up to 1700 µg, and, B, administration (1700 µg)...
Allergen‐specific immunoglobulins of the Immunoglobulin A (IgA) type have been found in nasal fluid patients with allergic rhinitis. IgA may play a protective role, but there are also data which show that allergen‐specific can induce eosinophil degranulation. The aim this study was to quantitate Bet v 1‐specific relation total children birch pollen‐induced intermittent rhinitis and healthy controls, after allergen challenge during natural pollen season. Eosinophil cationic protein (ECP),...
Duodenal biopsy specimens from 80 patients with chronic renal failure, who were undergoing haemodialysis, examined by light microscopy for evidence of inflammation, gastric metaplasia, and Campylobacter pylori infection. Chronic duodenitis was present in 47 (59%) patients, whom only seven (9%) showed active inflammation. Gastric metaplasia 50 (62.5%) yet identified two (2.5%). It is suggested that the duodenal environment failure remains hostile to growth these organisms spite presence metaplasia.